Recent Articles
In Aspen, a Bipartisan Strategy for Ibogaine Takes Shape as Advocates Confront the Limits of Traditional Rehab
ASPEN, Colorado — The drive into the Aspen Meadows Resort, with its open mountain views and Bauhaus-inspired architecture, offered a tranquil approach to what became one of the most strategically focused psychedelic policy gatherings of the year. Inside, at the Americans for Ibogaine (AFI) convening, the mood was not utopian but pragmatic — a coalition […]
By Joe Moore
MDMA-Assisted Therapy for the Wounded Healer: Help fund a pioneering study!
By Ivar W. Goksøyr
Filter
Bridging Worlds: Psychedelics, Community, and the Work of Our Time
In 2025, the psychedelic landscape is rich with possibility, and yet often fragmented. Psychedelic gatherings…
By Daniel Hugo Miceli
Growing Attention To Psychedelics For Pain, Physical & Neurological Conditions
By Kevin Lenaburg and Court Wing Psychedelics can be powerful treatments for chronic pain and…
By Kevin Lenaburg and Court Wing
Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs Our Protection
The Sonoran Desert toad (Incilius alvarius, formerly Bufo alvarius) produces 5-MeO-DMT in its skin. Demand…
By Joe Moore
GLP-1 Drugs, Psilocybin Mushrooms, and the Case for Sublingual Psilocin
More people than ever are taking GLP-1 receptor agonists—drugs like Ozempic (semaglutide), Wegovy, and Mounjaro.…
By Joe Moore
Psilocybin Enters German Psychiatry: A Clinical Milestone for Mental Health
Germany’s decision to permit psilocybin therapy for patients with treatment-resistant depression—under a compassionate use policy—marks…
By Joe Moore
It’s Time to Push Back: Meta’s War on Psychedelic Voices
META is doing real damage to the psychedelic ecosystem.Shadowbans. Post removals. Account suspensions. Entire orgs—especially…